Molecular Marker Predicts Patients Most Likely to Benefit Longest From Two Popular Cancer Drugs
Preliminary study needs further confirmation.
Read MorePosted by Judy O'Rourke | Sep 9, 2013 | Molecular Diagnostics, Pancreatic, Research |
Preliminary study needs further confirmation.
Read MorePosted by Judy O'Rourke | Sep 4, 2013 | Molecular Diagnostics |
Molecular biology is continuing to revolutionize disease diagnosis. Modern molecular tests based on the detection of nucleic acids (ie, DNA and RNA) offer considerable advantages over traditional methods of pathogen detection.
Read MorePosted by Clinical Lab Products | Aug 26, 2013 | Cancer, Molecular Diagnostics |
The new, nearly $1.5 million contract with further the development of a panel of assays designed to provide a fast and accurate way to identify and characterize biomarkers estimated to constitute up to 9% of NSCLC cases.
Read MorePosted by Judy O'Rourke | Aug 23, 2013 | Molecular Diagnostics |
The company is working with payors nationwide to make this test available to clinicians and cancer patients.
Read MorePosted by Clinical Lab Products | Aug 15, 2013 | Cancer, Heart Disease, Miscellaneous |
Mid America Clinical Laboratories is a joint venture clinical laboratory owned by Quest Diagnostics, Community Health Network, St. Vincent Health, and CoLab.
Read More